<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:epub="http://www.idpf.org/2007/ops" lang="en">
<head>
<meta http-equiv="default-style" content="application/xhtml+xml; charset=utf-8" />
<title>Clinical Anesthesia Fundamentals, 2e</title>
<link rel="stylesheet" type="text/css" href="css/style.css"/>
</head>
<body epub:type="bodymatter">
<div id="main_container">
<section epub:type="division">
<h4 class="h4" id="sec235">II. Chronic Medical Problems and Management in Patients Undergoing Vascular Surgery</h4>
<p class="nonindent">The patient undergoing vascular surgery likely has systemic vascular disease complicated by medical problems such as coronary artery disease (CAD), systemic hypertension, hyperlipidemia, diabetes, obesity, and tobacco abuse.</p>
<p class="headd"><em><strong>Did You Know?</strong></em></p>
<div class="boxd">
<p class="dify">During carotid endarterectomy, emboli from the surgical site are the most common cause of stroke.</p>
</div>
<h5 class="h5" id="sen659">A. CAD in Patients With Peripheral Vascular Disease</h5>
<p class="nonindent">As many as 25% of patients presenting for vascular surgery have severe CAD. The American Heart Association and others have published guidelines for cardiac evaluation and management prior to noncardiac surgery (<strong><a href="#ff37-2">Figure 37.2</a></strong>).<sup><a href="ch037-sec07.xhtml#bib1">1</a></sup></p>
<h5 class="h5" id="sen660">B. Preoperative Coronary Revascularization</h5>
<p class="nonindent">The Coronary Artery Revascularization Prophylaxis trial randomized patients with coronary disease before elective vascular surgery to either coronary revascularization or medical therapy and found no benefit to coronary revascularization if aggressive medical therapy (including beta blockers, aspirin, and statins) was instituted. <strong><em>Revascularization</em></strong> may therefore be of minimal value in preventing coronary events after vascular surgery, except in patients in whom revascularization is indicated for acute coronary syndrome. If a <strong><em>coronary stent</em></strong> is placed, elective surgery should be delayed: for bare metal stents, a minimum of 30&#x00A0;days of dual antiplatelet therapy (DAPT) with aspirin and a P2Y<sub>12</sub> inhibitor; and for drug-eluting stents, 6&#x00A0;months (or longer) of DAPT. Aspirin is recommended indefinitely to prevent in-stent thrombosis. In the event that surgery cannot be delayed in patients undergoing DAPT after coronary stent implantation and the procedure requires discontinuation of P2Y<sub>12</sub> inhibitor therapy, it is recommended to continue aspirin perioperatively and restart the P2Y<sub>12</sub> inhibitor as early as possible postoperatively.<sup><a href="ch037-sec07.xhtml#bib2">2</a></sup> With the advent of new stents, the time required for DAPT and delay of surgery continues to evolve.</p>
<a id="page786"></a>
<div class="table">
<p class="TABLEpNUM" id="tt37-1"><strong><span class="tab">Table&#160;37.1</span> Medical Therapy, Side Effects, and Current Recommendations</strong></p>
<table class="table">
<colgroup>
<col style="width:25%;"></col>
<col style="width:35%;"></col>
<col style="width:40%;"></col>
</colgroup>
<tr>
<td class="theadleft"><strong>Medication/Drug Class</strong></td>
<td class="theadleft"><strong>Side Effects</strong></td>
<td class="theadleft"><strong>Perioperative Recommendations</strong></td>
</tr>
<tr>
<td class="td2"><p class="tbodyleft"><strong>Aspirin</strong></p></td>
<td class="td2"><p class="tbodyleft">Platelet inhibition may lead to increased bleeding</p>
<p class="tbodyleft">Decreased GFR</p></td>
<td class="td2"><p class="tbodyleft">Continue until day of surgery, especially for carotid and peripheral vascular cases.</p>
<p class="tbodyleft">Monitor fluid and urine output.</p></td>
</tr>
<tr>
<td class="td3"><p class="tbodyleft"><strong>Clopidogrel</strong></p></td>
<td class="td3"><p class="tbodyleft">Platelet inhibition may lead to increased bleeding</p>
<p class="tbodyleft">Rare thrombotic thrombocytopenic purpura</p></td>
<td class="td3"><p class="tbodyleft">Hold for 7&#x00A0;d before surgery except for CEA and severe CAD or DES.</p>
<p class="tbodyleft">Cross-match blood.</p>
<p class="tbodyleft">Avoid neuraxial anesthesia if not held at least 7&#x00A0;d.</p></td>
</tr>
<tr>
<td class="td2"><p class="tbodyleft"><strong>HMG CoA reductase inhibitors (statins)</strong></p></td>
<td class="td2"><p class="tbodyleft">Liver function test abnormalities</p>
<p class="tbodyleft">Rhabdomyolysis</p></td>
<td class="td2"><p class="tbodyleft">Assess liver function tests.</p>
<p class="tbodyleft">Continue through morning of surgery and continue as soon as possible postoperatively.</p>
<p class="tbodyleft">Check CPK if myalgias.</p></td>
</tr>
<tr>
<td class="td3"><p class="tbodyleft"><strong>Beta blockers</strong></p></td>
<td class="td3"><p class="tbodyleft">Bronchospasm</p>
<p class="tbodyleft">Hypotension</p>
<p class="tbodyleft">Bradycardia, heart block</p>
<p class="tbodyleft">Induction hypotension</p>
<p class="tbodyleft">Cough</p></td>
<td class="td3"><p class="tbodyleft">Continue through perioperative period.</p></td>
</tr>
<tr>
<td class="td2"><p class="tbodyleft"><strong>ACE inhibitors</strong></p></td>
<td class="td2"><p class="tbodyleft">Induction hypotension</p>
<p class="tbodyleft">Cough</p></td>
<td class="td2"><p class="tbodyleft">Continue through perioperative period.</p>
<p class="tbodyleft">Consider one-half dose on day of surgery.</p></td>
</tr>
<tr>
<td class="td3"><p class="tbodyleft"><strong>Diuretics</strong></p></td>
<td class="td3"><p class="tbodyleft">Hypovolemia</p>
<p class="tbodyleft">Electrolyte abnormalities</p></td>
<td class="td3"><p class="tbodyleft">Continue through morning of surgery.</p>
<p class="tbodyleft">Monitor fluid and urine output.</p></td>
</tr>
<tr>
<td class="td2"><p class="tbodyleft"><strong>Calcium channel blockers</strong></p></td>
<td class="td2"><p class="tbodyleft">Perioperative hypotension (especially with amlodipine)</p></td>
<td class="td2"><p class="tbodyleft">Continue through perioperative period.</p>
<p class="tbodyleft">Consider withholding amlodipine on day of surgery.</p></td>
</tr>
<tr>
<td class="td3"><p class="tbodyleft"><strong>Oral hypoglycemics</strong></p></td>
<td class="td3"><p class="tbodyleft">Hypoglycemia intraoperatively and perioperatively</p>
<p class="tbodyleft">Lactic acidosis with metformin</p></td>
<td class="td3"><p class="tbodyleft">When feasible, switch to insulin preoperatively.</p>
<p class="tbodyleft">Monitor glucose status intraoperatively and perioperatively.</p></td>
</tr>
</table>
<p class="tfoot">ACE, angiotensin-converting enzyme; CAD, coronary artery disease; CEA, carotid endarterectomy; CPK, creatine phosphokinase; DES, drug-eluting stents; GFR, glomerular filtration rate; HMG CoA, 3-hydroxy-3-methylglutaryl coenzyme A.</p>
<p class="u_tfoot">Derived from Morgan GE, Mikhail MS, Murray MJ, eds. <em>Clinical Anesthesiology</em>. 4th ed. Lange Medical Books/McGraw-Hill; 2006.</p>
</div>
<a id="page787"></a>
<div class="figureu5" id="ff37-2"><figure class="figure"><img src="images/ff37-2.jpg" alt="img"/><figcaption class="ucaption"><span class="u_fignum">Figure&#160;37.2</span> <strong>Stepwise approach to perioperative cardiac assessment for coronary artery disease. The American College of Cardiology/American Heart Association (ACC/AHA) guideline calls for stepwise cardiac risk assessment involving consideration of the patient&#x2019;s cardiac risk factors, functional capacity, and the planned surgical procedure. ACS, acute coronary syndrome; CAD, coronary artery disease; CPG, Clinical Practice Guidelines; GDMT, guidelinedirected medical therapy; MACE, major adverse cardiac event; METs, metabolic equivalents.</strong> (From Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <em>J Am Coll Cardiol</em>. 2014;64(22):e77-e137. doi:10.1016/j.jacc.2014.07.944)</figcaption></figure></div>
</section>
</div>
</body>
</html>